

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-227)

VICASINABIN

PRONUNCIATION

vye" ka sin' ab in

THERAPEUTIC CLAIM


Treatment of pain/analgesic and diabetic retinopathy

CHEMICAL NAMES

3-Pyrrolidinol, 1-[5-(1,1-dimethylethyl)-3-[(1-methyl-1*H*-tetrazol-5-yl)methyl]-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-7-yl]-, (3*S*)-

(3*S*)-1-{5-*tert*-butyl-3-[(1-methyl-1*H*-tetrazol-5-yl)methyl]-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-7-yl}pyrrolidin-3-ol

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₁₅H₂₂N₁₀O

MOLECULAR WEIGHT

358.40

TRADEMARK

None as yet

SPONSOR

Genentech, Inc./Hoffmann-La Roche Inc.

CODE DESIGNATIONS

RG7774; RO6868847

CAS REGISTRY NUMBER

1433361-02-4

UNII

QJ8UO6C05M

WHO NUMBER

11940

gbk